CLLS - Cellectis SA Debt to Book Capitalization Ratio

Cellectis S.A. (CLLS) faces production challenges for gene therapies due to the complexity of working with live cells, which limits process automation. The company leads in genome modification via the TALEN system, investing heavily in R&D. The business relies on an autonomous cycle independent of the broader economy, giving the asset defensive qualities. The current indicator is 2.66. This chart illustrates the company's valuation.

CLLS Cellectis SA: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for cellectis.com (CLLS)

- price and consensus price forecast:

Stock Price Cellectis|CLLS - Consensus Target

- market capitalization data:

Market Value CLLS|CLLS - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Cellectis S.A.|CLLS - Company Book Value|Market Value to Book Value Ratio cellectis.com|CLLS - Company Assets

- debt and liquidity data:

Total Debt to Capital Cellectis S.A.|CLLS - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Cellectis|CLLS - Company Cumulative Debt|Debt to Book Value CLLS

Analysis of all company metrics:CLLS, Cellectis Biotherapeutics

This ratio determines the share of total liabilities within the equity structure, allowing for an assessment of the financial leverage level and the business's dependence on borrowed funds. Analyzing the extent to which balance sheet capital is covered by debt obligations serves as a stress test for the stability of Cellectis S.A. (CLLS), whose capital expenditures on gene editing robotization and laboratory automation require balanced financing to minimize default risks.

Competitors of Cellectis S.A.